Can letermovir improve immune health in older HIV patients?
Treatments studied
Part of Infections clinical trials.
This study tests whether a drug called letermovir can help keep the immune system calm and healthy in people over 50 with well-controlled HIV. It might reduce immune overactivation that can lead to other health problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your HIV is well-controlled (viral load below 50 copies/mL) for more than a year.
- You are at least 50 years old.
- Your CD4 count (a marker of immune health) has ever been 200 or lower.
- You have been on antiretroviral therapy for at least 6 months.
- You have had a past infection with cytomegalovirus (CMV) but no active CMV disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether letermovir can help prevent CMV (a common virus after transplant) from coming back after you’ve already been treated. If you qualify, you may be offered letermovir as “secondary prevention” and followed for about 6 months.
This trial tests whether taking letermovir for a longer time can prevent CMV (a common virus) from reactivating in adults with certain risk factors after a donor stem cell transplant. If you're preparing for your first transplant and have a high-risk donor or conditioning, this study may be an option.
This trial tests if the drug letermovir can prevent a common virus (CMV) in children who have certain blood disorders and are getting a stem cell transplant. It aims to keep you safer during recovery.
This study tests whether a diabetes drug called metformin can improve the immune system and help keep the HIV virus under control in people who are already doing well on HIV treatment. If you are over 40 and have had a stable viral load for a year, this could be a way to boost your immune health.
This study tests how a single dose of an antiviral medicine called letermovir behaves in people with severe kidney disease, with or without regular haemodialysis. It aims to find the right dose for this population to prevent or treat infections.
This trial tests whether the medicine letermovir can prevent a common virus (CMV) from coming back after an allogeneic stem cell transplant in children. It may help lower the risk of CMV infection during the vulnerable period right after transplant.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.